233 related articles for article (PubMed ID: 12189360)
1. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
Pfister M; Labbé L; Lu JF; Hammer SM; Mellors J; Bennett KK; Rosenkranz S; Sheiner LB;
Clin Pharmacol Ther; 2002 Aug; 72(2):133-41. PubMed ID: 12189360
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
Sadler BM; Gillotin C; Lou Y; Eron JJ; Lang W; Haubrich R; Stein DS
Antimicrob Agents Chemother; 2001 Dec; 45(12):3663-8. PubMed ID: 11709366
[TBL] [Abstract][Full Text] [Related]
3. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
4. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.
Decker CJ; Laitinen LM; Bridson GW; Raybuck SA; Tung RD; Chaturvedi PR
J Pharm Sci; 1998 Jul; 87(7):803-7. PubMed ID: 9649346
[TBL] [Abstract][Full Text] [Related]
6. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Schütt M; Zhou J; Meier M; Klein HH
J Endocrinol; 2004 Dec; 183(3):445-54. PubMed ID: 15590971
[TBL] [Abstract][Full Text] [Related]
8. Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats.
Gao W; Kageyama M; Inoue Y; Tadano J; Fukumoto K; Fukushima K; Yamasaki D; Nishimura A; Yoshikawa Y; Shibata N; Takada K
Biol Pharm Bull; 2003 Feb; 26(2):199-204. PubMed ID: 12576680
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction.
Marzolini C; Telenti A; Buclin T; Biollaz J; Decosterd LA
J Chromatogr B Biomed Sci Appl; 2000 Mar; 740(1):43-58. PubMed ID: 10798293
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.
Pfister M; Labbé L; Hammer SM; Mellors J; Bennett KK; Rosenkranz S; Sheiner LB;
Antimicrob Agents Chemother; 2003 Jan; 47(1):130-7. PubMed ID: 12499180
[TBL] [Abstract][Full Text] [Related]
11. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.
Eagling VA; Wiltshire H; Whitcombe IW; Back DJ
Xenobiotica; 2002 Jan; 32(1):1-17. PubMed ID: 11824416
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
[TBL] [Abstract][Full Text] [Related]
13. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
Condra JH; Petropoulos CJ; Ziermann R; Schleif WA; Shivaprakash M; Emini EA
J Infect Dis; 2000 Sep; 182(3):758-65. PubMed ID: 10950769
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography.
Poirier JM; Robidou P; Jaillon P
Ther Drug Monit; 2002 Apr; 24(2):302-9. PubMed ID: 11897976
[TBL] [Abstract][Full Text] [Related]
16. Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals.
Morse GD; Rosenkranz S; Para MF; Segal Y; Difrancesco R; Adams E; Brizz B; Yarasheski KE; Reichman RC
Antimicrob Agents Chemother; 2005 Aug; 49(8):3373-81. PubMed ID: 16048950
[TBL] [Abstract][Full Text] [Related]
17. Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model.
Shibata N; Gao W; Okamoto H; Kishida T; Iwasaki K; Yoshikawa Y; Takada K
J Pharm Sci; 2002 Mar; 91(3):680-9. PubMed ID: 11920753
[TBL] [Abstract][Full Text] [Related]
18. Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice.
Lenhard JM; Croom DK; Weiel JE; Spaltenstein A; Reynolds DJ; Furfine ES
J Nutr; 2000 Sep; 130(9):2361-6. PubMed ID: 10958836
[TBL] [Abstract][Full Text] [Related]
19. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Gupta A; Zhang Y; Unadkat JD; Mao Q
J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102
[TBL] [Abstract][Full Text] [Related]
20. High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction.
Dailly E; Thomas L; Kergueris MF; Jolliet P; Bourin M
J Chromatogr B Biomed Sci Appl; 2001 Jul; 758(2):129-35. PubMed ID: 11486821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
